Ubrelvy (ubrogepant) is AbbVie’s oral CGRP receptor blocker for stopping a migraine attack once it has started. Unlike the preventive drugs in the same class, it is taken only when you need it, which makes its cash cost unusually dependent on how many attacks you actually treat.
AbbVie is one of the few manufacturers that publishes a plain list price on the drug’s consumer site, so this page can compare a real list price, a real pharmacy acquisition cost and a real retail cash price against each other. Everything below was verified on September 2, 2026. This is a cost and paperwork guide only, with no medical advice.
What Does Ubrelvy Cost Without Insurance?
Ubrelvy comes in 50 mg and 100 mg strengths, in boxes of 10, 16 or 30 single-dose packets. AbbVie prices a 30-day supply, which is the 10-count box, so that is the unit used throughout. The list-price row comes from AbbVie’s own cost page. The acquisition-cost row is CMS’s National Average Drug Acquisition Cost survey, which measures what retail pharmacies pay their wholesalers. Retail cash figures come from SingleCare’s live Ubrelvy page, prices updated September 2, 2026.
| Price point | Low | Average / typical | High |
|---|---|---|---|
| Box of 10 (100 mg), cash with a free discount card | $1,040.83 | $1,096.80 | $1,123.36 |
| Box of 10 (100 mg), average retail cash (no card) | $1,491.11 | $1,491.11 | $1,491.11 |
| AbbVie published list price (WAC), 30-day supply | $1,139.09 | $1,139.09 | $1,139.09 |
| Pharmacy acquisition cost (NADAC), per 100 mg tablet | $109.14 | $109.14 | $109.14 |
| Pharmacy acquisition cost (NADAC), per 50 mg tablet | $108.91 | $108.91 | $108.91 |
| Per dose, cash range | $104.08 | $113.91 | $149.11 |
| Medicare Part D average per fill, 2024 | $1,308.72 | $1,308.72 | $1,308.72 |
| UBRELVY Complete Savings Card (commercial insurance only) | $0 | $0 | $0 |
| myAbbVie Assist (approved applicants) | $0 | $0 | $0 |
The cross-source range for one box of 10 is roughly $1,041 to $1,491, and the sources disagree in a predictable direction. AbbVie’s stated list price of $1,139.09 as of January 2026 sits between the best card price and the average retail price, because retail cash adds a pharmacy markup on top of list. NADAC’s $109.14 per 100 mg tablet, effective August 19, 2026, comes to $1,091.35 for ten tablets, about 96% of AbbVie’s list price. Two entirely independent sources landing that close together is strong evidence both figures are accurate.
One notable quirk: strength does not change the price
NADAC prices the 50 mg tablet at $108.91 and the 100 mg tablet at $109.13, a difference of 22 cents. AbbVie prices a 30-day supply the same either way. If your prescriber writes 50 mg, you are not saving money on the drug, only on the milligrams.
What Medicare pays
CMS’s Medicare Part D Spending by Drug dataset, data year 2024, records Ubrelvy at $102.07 per dosage unit and $1,308.72 per claim across 328,213 claims and 83,437 beneficiaries, with $429.5 million in total Part D spending and $5,148.05 per beneficiary for the year. Those numbers are gross of manufacturer rebates, so they run high, but they confirm the scale.
What Drives the Price
No marketed generic. FDA’s Drugs@FDA database shows generic ubrogepant applications from Aurobindo, Zydus and MSN Laboratories, with tentative approvals recorded between May 2025 and June 2026. Tentative approval means FDA is satisfied with the product but patents or exclusivity block the launch. Until one actually reaches pharmacies there is no cheaper equivalent, and CMS’s NADAC file carries no corresponding generic price.
How many attacks you treat. Ubrelvy is billed per tablet. The FDA label allows a second 100 mg dose at least 2 hours after the first, up to 200 mg in 24 hours, and notes that the safety of treating more than 8 migraines in a 30-day period has not been established. Someone who treats eight attacks and repeats a dose on half of them can burn through 12 tablets a month, so box size matters more than most people plan for.
Box size on the prescription. Boxes of 10, 16 and 30 all exist. Because the price is essentially linear per tablet, a 30-count box does not buy you a bulk discount, it just triples the amount you pay up front. Fill the smallest box that covers your realistic month.
Which pharmacy you use. On September 2, 2026, card prices for the identical 10-count box ranged from $1,040.83 to $1,123.36 across chains, an 8% spread. Bear in mind that a single named chain’s card price shifts between visits, so treat the spread as a reason to call around rather than as a quote you can rely on for a specific store.
Regional and pharmacy-type variation. Grocery-chain and independent pharmacies frequently price brand-only drugs below the big drugstore chains, and the gap widens in lower-cost metros. It is worth pricing the same script at three pharmacies before you transfer it.
Cash Price vs. Insurance
If you have commercial insurance and the plan covers Ubrelvy, insurance wins outright: AbbVie’s UBRELVY Complete Savings Card can take an eligible patient’s copay to as little as $0, with savings capped at $7,000 per calendar year. That card is off limits to anyone uninsured and to anyone on Medicare, Medicaid, TRICARE or another government program.
The usual complication is prior authorization and step therapy. Many plans require a documented failure of one or more generic triptans before they will pay for a gepant. Until that clears, you are paying cash even though you are insured, and every tactic below applies.
For the uninsured, there is no version of this drug that is cheap. The gap between the best card price and average retail is about $450 on a single box, which is the largest saving most people will find without paperwork. Compare against Nurtec ODT, the other acute oral gepant, before you settle: it is priced per dose in the same neighborhood but sold in packs of 8 rather than 10.
How to Pay Less
Use a free discount card every single fill. The difference between SingleCare’s average retail price of $1,491.11 and its best card price of $1,040.83 is roughly $450 on one box, or 30%. There is no eligibility requirement and no fee. Our comparison of GoodRx vs. SingleCare walks through which card tends to win on brand-only drugs and how to check both in two minutes.
Apply to myAbbVie Assist. AbbVie’s patient assistance program provides its medicines free to patients with limited or no insurance who meet published income criteria. AbbVie’s own income table sets the thresholds at $63,840 or less for a household of one, $86,560 for two, $109,280 for three and $132,000 for four, adding $22,720 for each additional dependent. Those are generous limits by patient-assistance standards, and a great many uninsured people clear them. Note AbbVie’s exclusion: patients whose commercial plan requires them to apply as a condition of coverage (an alternate funding program) are not eligible.
Ask for the smallest box that covers your month. Because the price is close to linear per tablet, a 30-count prescription is simply three times the cash outlay of a 10-count. If your attack frequency is 4 to 6 a month, a 10-count box is usually the right fill.
Look at generic triptans as a price anchor. Generic sumatriptan is in a different universe on cost: CMS’s NADAC file puts the 100 mg tablet at $0.43 as of August 19, 2026. That is not clinical advice, and gepants exist precisely because triptans fail or are contraindicated for many people. But if price is the binding constraint, raise it with your prescriber, and see sumatriptan cash prices for what pharmacies charge.
Try a federally qualified health center. Community health centers charge on a sliding scale and many operate 340B pharmacies that dispense brand drugs well below retail. Our guide to free and sliding-scale clinics covers how to find one and what to bring to the appointment.
Sanity-check any quote you are given. Cash prices at the counter vary far more than people expect. Run the number through our fair price checker before you hand over a card.
The Bottom Line
Ubrelvy is a four-figure cash drug, and tentative generic approvals do not change that until one of them actually launches. As of September 2026 the realistic uninsured range is $1,041 to $1,491 for a box of 10, with the free discount card doing most of the work.
If your household income is under AbbVie’s published thresholds, myAbbVie Assist is the highest-value move on this page and can take the cost to zero. If you need prevention rather than acute treatment, the comparison to run is Qulipta and the injectable CGRP options, Emgality, Ajovy, Aimovig and Vyepti, where the pricing model is monthly rather than per attack.